Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Escapes COVID Impact With 2% Underlying Growth

R&D Spend To Rise 15%

Executive Summary

Takeda continued to prove largely resistant to the business impact of the pandemic last fiscal year, when it made solid progress and exceeded a number of post-Shire targets. R&D spending is set to ramp-up as the Japanese firm progresses its 'Wave 1' pipeline to market. 

You may also be interested in...



APAC Life Sciences Valuation Trends: Chinese Firms Eclipse Japan, India Peers

Chinese healthcare and life sciences firms now overshadow their peers in Japan and India in terms of key valuation metrics amid COVID-19 and China has also witnessed significant M&A activity at high revenue multiples.

Takeda Confirms $2.3bn Deal With Blackstone For Japan Consumer Business

In a widely anticipated move, Takeda has confirmed the sale of its consumer healthcare business in Japan, to the US private equity group Blackstone.

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel